In October 2023, shortly after uprooting from her long-term home in Essex, Massachusetts, Barbara Doyle, then 70, started experiencing massive nosebleeds. Doyle and her husband, Craig, had just moved ...

Early-onset cancers are rising worldwide, and this Cell Perspective argues that cancer prevention must move beyond static ...

Early detection plays a critical role in improving outcomes. Today, diagnosis typically relies on video nasal endoscopy and ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

The FDA approval for Ponlimsi is based on comprehensive evidence, including analytical and clinical data.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Have you considered getting a second opinion on that mysterious rash?

Exdensur was approved in China as the first and only ultra-long-acting biologic for adult patients suffering from chronic rhinosinusitis with nasal polyps, according to a Wednesday filing. The disease ...